Oxford BioMedica extends licence for viral vector technology

Licence agreement

Gene therapy specialist Oxford BioMedica plc said it has expanded an existing licence agreement for its LentiVector gene delivery technology with a major (unnamed) multinational pharmaceutical company. The amendment broadens the agreement from an annual license for use for research activities in the US to a worldwide perpetual licence.

Under the terms of the amended agreement, Oxford BioMedica will receive a one-time undisclosed payment from the licensee, but no further financial details were not disclosed.

LentiVector, can be used to deliver genes to a wide range of cell and tissue types and has applications gene therapy and as a tool for drug discovery.